TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12821477

Group type: EXPERIMENTAL
Intervention: Garenoxacin 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Garenoxacin 1200 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Garenoxacin (100 to 400 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Garenoxacin (400 mg and above)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Garenoxacin (all doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10370688

Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pancreatojejunostomy
Number of subjects: 23
Study: 8934255

Group type: EXPERIMENTAL
Intervention: Doubling the amount of LH administered
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard amount of LH administered
Number of subjects: 80
Study: 1766100

Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg.kg‐1), n = 6
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg.kg‐1), n = 7
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline/Placebo, n = 6
Number of subjects: 19
Study: 6350615

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin for 5 days postoperatively
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin for 10 days postoperatively
Number of subjects: 223

Group type: COMPARATOR
Intervention: No postoperative antibiotics
Number of subjects: 223
Study: 30714750

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nondirective therapy (ND)
Number of subjects: 66
Study: 29172593

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (iCBT) program for health anxiety (n = 45)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Active psychoeducation control group (n = 41)
Number of subjects: 86
Study: 26350992

Group type: EXPERIMENTAL
Intervention: Nongrooved incisions
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Grooved incisions
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 24629303

Group type: EXPERIMENTAL
Intervention: Scripted verbal or written consent process (group I)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Web-based, audiovisual presentation (group II)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Both interventions (group I and group II)
Number of subjects: 102
Study: 22001100

Group type: EXPERIMENTAL
Intervention: 70-W high-power Ho:YAG laser lithotripsy
Number of subjects: 273

Group type: COMPARATOR
Intervention: 30-W low-power Ho:YAG laser lithotripsy
Number of subjects: 273
Study: 20117707

Group type: EXPERIMENTAL
Intervention: Biaxial microincision phacoemulsification (<1.5 mm)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Coaxial small-incision phacoemulsification (2.8 mm)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 94
Study: 17870048

Group type: EXPERIMENTAL
Intervention: Dacryocystoplasty (Lacricath) and silicone intubation (Ritleng)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Silicone intubation alone
Number of subjects: 70
Study: 15976999

Group type: EXPERIMENTAL
Intervention: VO2 kinetics during repeated sprint exercise (RSE)
Number of subjects: 11
Study: 12190656

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 10652036

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Enalapril (N = 21)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Enalapril (N = 11)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 102
Study: 8655928

Group type: EXPERIMENTAL
Intervention: D5W
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1/2NS
Number of subjects: 12
Study: 1325889

Group type: EXPERIMENTAL
Intervention: Dentifrice containing soluble pyrophosphate
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control MFP dentifrice
Number of subjects: 88
Study: 6832462

Group type: EXPERIMENTAL
Intervention: 200 mg indobufen administered orally or by i.v. injection
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30216492

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 5148

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 5148

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 5148
Study: 28758526

Group type: EXPERIMENTAL
Intervention: Oral Reading Fluency (ORF) slope
Number of subjects: 102
Study: 27474232

Group type: EXPERIMENTAL
Intervention: Patients not enrolled on AAML0531 trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients enrolled on AAML0531 trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonenrollment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 0
Study: 25220196

Group type: EXPERIMENTAL
Intervention: Copeland HHRI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Global C.A.P. HHRI
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Revised HHRI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonrevised HHRI
Number of subjects: 32
Study: 22038501

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 112
Study: 20307702

Group type: EXPERIMENTAL
Intervention: Training program
Number of subjects: 185

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 185
Study: 18069601

Group type: EXPERIMENTAL
Intervention: Cardioversion of atrial fibrillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies for stroke prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate control drugs (old and new)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical management of AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ablation of perivenous pulmonary circuits, ablation of the AV node, and implantation of a pacemaker
Number of subjects: 0
Study: 16096180

Group type: EXPERIMENTAL
Intervention: 0.03% or 0.1% tacrolimus ointment applied twice daily
Number of subjects: 9813
Study: 12030342

Group type: EXPERIMENTAL
Intervention: Nicorandil (3 mg/h infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12502274

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention including classroom-based curriculum, parent training, and home visits.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group (not specified what the control intervention was).
Number of subjects: 0
Study: 12799953

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Butylscopolamine 20 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 7516295

Group type: EXPERIMENTAL
Intervention: Human, recombinant GH (Genotropin, Kabi Pharmacia, Uppsala, Sweden) at a dosage of 0.1 IU/kg body weight per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Human, recombinant GH (Genotropin, Kabi Pharmacia, Uppsala, Sweden)
Number of subjects: 40
Study: 2680176

Group type: EXPERIMENTAL
Intervention: Oral photochemotherapy (PUVA) for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (covered skin)
Number of subjects: 14
Study: 769721

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Levoamphetamine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both (Levoamphetamine and Dextroamphetamine)
Number of subjects: 31
Study: 7305656

Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride therapy after surgery
Number of subjects: 15

Group type: COMPARATOR
Intervention: No propranolol hydrochloride therapy after surgery
Number of subjects: 15
Study: 31128957

Group type: EXPERIMENTAL
Intervention: Dating Matters
Number of subjects: 2349

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2349
Study: 28975661

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance and Impact Training (HiRIT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (home-based, low-intensity exercise program)
Number of subjects: 101
Study: 26843131

Group type: EXPERIMENTAL
Intervention: NIR imaging after systemic indocyanine green (ICG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional margin assessment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NIR imaging after systemic ICG
Number of subjects: 12
Study: 25380675

Group type: EXPERIMENTAL
Intervention: IRX (45 min of cycling)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: IRC (control trial without physical activity)
Number of subjects: 17
Study: 22175695

Group type: EXPERIMENTAL
Intervention: Water treatment and hygiene promotion (WT & HP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sanitation improvement in combination with WT & HP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20074412

Group type: EXPERIMENTAL
Intervention: Enhanced DOTS (DOTS-A)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Routine DOTS
Number of subjects: 650
Study: 18948639

Group type: EXPERIMENTAL
Intervention: Osteopathy in the cranial field, myofascial release, or both (OMT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (nontherapeutic attention)
Number of subjects: 55
Study: 16211739

Group type: EXPERIMENTAL
Intervention: Granisetron 0.1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 0.2 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 0.3 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron (all doses)
Number of subjects: 100
Study: 12423702

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol‐17‐beta with progestins
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Change in androstenedione levels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum concentration of estradiol‐17‐beta
Number of subjects: 60
Study: 10606212

Group type: EXPERIMENTAL
Intervention: Calcium HMB supplementation (3 to 6 g x d(‐1))
Number of subjects: 40
Study: 8947787

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 1747493

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg tid)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clebopride (0.5 mg tid)
Number of subjects: 48
Study: 7107939

Group type: EXPERIMENTAL
Intervention: Videotapes depicting alcoholics with varying race and socioeconomic status
Number of subjects: 40
Study: 31166987

Group type: EXPERIMENTAL
Intervention: 15, 30 or 60 μg/strain of quadrivalent virus-like particle (QVLP) vaccine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 7.5 or 15 μg/strain of QVLP with alum
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 30 μg QVLP vaccine
Number of subjects: 2
Study: 29257792

Group type: EXPERIMENTAL
Intervention: Mixed high volume and high intensity (MP) resistance training program (10-12 reps at 65%-70% of 1RM for lower body; HI protocol for upper body)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High intensity (HI) resistance training program (4-5 reps at 88%-90% of 1RM for both upper and lower body)
Number of subjects: 20
Study: 26565438

Group type: EXPERIMENTAL
Intervention: Hybrid Constraint Induced Movement Therapy (hCIMT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Distributed individual occupational therapy (OT)
Number of subjects: 44
Study: 23852397

Group type: EXPERIMENTAL
Intervention: S-1 plus weekly split-dose cisplatin (SWP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: S-1 plus standard-dose cisplatin (SP)
Number of subjects: 37
Study: 23065071

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 17500

Group type: EXPERIMENTAL
Intervention: Low-dose tricyclic antidepressants
Number of subjects: 17500
Study: 20391513

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Denosumab 180 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 17708846

Group type: EXPERIMENTAL
Intervention: Glutamine treatment group (0.4 g/kg per day for 7 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (standard PN and EN without glutamine)
Number of subjects: 44
Study: 15560969

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 12776266

Group type: EXPERIMENTAL
Intervention: Long daily regimen (prednisolone 60 mg/m2 for 6 weeks, then 40 mg/m2 alternate-day for 6 weeks)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Long alternate-day regimen (prednisolone 60 mg/m2 for 4 weeks, then 60 mg/m2 alternate-day for 4 weeks, tapering by 10 mg/m2 every 4 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Both groups (Group A and Group B)
Number of subjects: 73
Study: 10367871

Group type: EXPERIMENTAL
Intervention: Oral contrast solution (OC)
Number of subjects: 394

Group type: COMPARATOR
Intervention: No oral contrast solution (no OC)
Number of subjects: 394
Study: 8566682

Group type: EXPERIMENTAL
Intervention: CBS 480 mg daily during 6 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: M 1 g daily during 6 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CBS 480 mg daily plus M 750 mg daily during 4 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CBS 480 mg daily plus Amoxycillin 1500 mg daily during 4 weeks
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: M 750 mg daily plus Amoxycillin 1500 mg daily during 4 weeks
Number of subjects: 114
Study: 2166253

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/die
Number of subjects: 23

Group type: COMPARATOR
Intervention: Quinapril 20 mg/die
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/die
Number of subjects: 23

Group type: COMPARATOR
Intervention: Quinapril 40 mg/die
Number of subjects: 23
Study: 7428405

Group type: EXPERIMENTAL
Intervention: Sustained-release clonidine (250 or 500 micrograms/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard tablet clonidine (300 or 450 micrograms/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sustained-release clonidine
Number of subjects: 24
Study: 30103252

Group type: EXPERIMENTAL
Intervention: Oral apixaban (10 mg twice daily for the first 7 days, then 5 mg twice daily)
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Subcutaneous dalteparin (200 IU/kg for the first month, then 150 IU/kg once daily)
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Oral apixaban
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Subcutaneous dalteparin
Number of subjects: 1168
Study: 26919301

Group type: EXPERIMENTAL
Intervention: Psychological First Aid (PFA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Social Acknowledgment Condition (Control)
Number of subjects: 42
Study: 24125790

Group type: EXPERIMENTAL
Intervention: Opt-out defaults (options visible and preselected)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Opt-in defaults (options visible but unselected)
Number of subjects: 45
Study: 22739038

Group type: EXPERIMENTAL
Intervention: 1% diquafosol ophthalmic solution
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 1% and 3% diquafosol ophthalmic solutions
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo ophthalmic solution
Number of subjects: 286
Study: 20406354

Group type: EXPERIMENTAL
Intervention: ParaPost
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: UniCore
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ribbond
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EverStick
Number of subjects: 80
Study: 18331269

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 25
Study: 15753792

Group type: EXPERIMENTAL
Intervention: Thyroglobulin (Tg) measurement <2 ng/ml
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Whole-body scan (WBS)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ablation dose (AD)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Stage of cancer
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 109
Study: 11965203

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 58511

Group type: COMPARATOR
Intervention: Thrombolysis with aspirin
Number of subjects: 58511
Study: 10372612

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 421

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 421
Study: 7560636

Group type: EXPERIMENTAL
Intervention: Cereal grain and grass allergies (Group 1)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Wheat allergy alone (Group 2)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Grass allergy alone (Group 3)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Wheat allergy (specific IgE binding)
Number of subjects: 145
Study: 1696663

Group type: EXPERIMENTAL
Intervention: Medetomidine (100 micrograms)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 5
Study: 7282852

Group type: EXPERIMENTAL
Intervention: Contact lenses fitted to alter myopic refractive error
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical manner contact lenses
Number of subjects: 0
Study: 31420034

Group type: EXPERIMENTAL
Intervention: Outreach program participants
Number of subjects: 2199
Study: 27535131

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) group-based enhancement to home visiting (HV/CBT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Home visiting as usual (HV)
Number of subjects: 95
Study: 26359192

Group type: EXPERIMENTAL
Intervention: School meals (intervention)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Packed lunch (control)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Baseline EPA+DHA status
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Intervention-induced increase in EPA+DHA status
Number of subjects: 726
Study: 23734617

Group type: COMPARATOR
Intervention: YA-only cohort
Number of subjects: 30
Study: 21894807

Group type: EXPERIMENTAL
Intervention: Prophylactic intra-aortic balloon pump (IABP) support during PCI
Number of subjects: 106

Group type: COMPARATOR
Intervention: PCI without IABP insertion (Control)
Number of subjects: 106
Study: 19366790

Group type: EXPERIMENTAL
Intervention: BMI at or above the 85th percentile
Number of subjects: 303

Group type: COMPARATOR
Intervention: BMI below the 85th percentile
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Physical activity self-concept and self-efficacy, diet self-efficacy
Number of subjects: 303
Study: 16776752

Group type: EXPERIMENTAL
Intervention: Intensive mixture therapy (IMT) using insulin lispro mixture 50/50 before breakfast and lunch and insulin lispro mixture 25/75 before dinner
Number of subjects: 60

Group type: COMPARATOR
Intervention: Insulin glargine therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intensive mixture therapy (IMT)
Number of subjects: 60
Study: 15220781

Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (INB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 52
Study: 11426092

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 0.25 mg intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9431382

Group type: EXPERIMENTAL
Intervention: Separate administration of DTaP, hepatitis B vaccine, and PRP-T vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination DTaP-hepatitis B vaccine-PRP-T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose of CRM197-OS
Number of subjects: 0
Study: 8033939

Group type: EXPERIMENTAL
Intervention: Antiplatelet medication
Number of subjects: 207

Group type: COMPARATOR
Intervention: No specific intervention mentioned for asymptomatic reinfarcts
Number of subjects: 207
Study: 2688718

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0
Study: 31050315

Group type: EXPERIMENTAL
Intervention: Tumor treating fields (TTFields) and maintenance temozolomide (TMZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone
Number of subjects: 0
Study: 25160492

Group type: EXPERIMENTAL
Intervention: Life-coaching intervention (one individualised face-to-face session and five telephone coaching sessions over 3 months)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Life-coaching intervention
Number of subjects: 11
Study: 24147111

Group type: EXPERIMENTAL
Intervention: Rocuronium in obstructive jaundice group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no obstructive jaundice)
Number of subjects: 53
Study: 21125466

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion 80 mmol/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pooled analysis from literature review (including pilot study)
Number of subjects: 60
Study: 18196417

Group type: EXPERIMENTAL
Intervention: Alumina ceramic liners
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene liners
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (nonoperated contralateral side)
Number of subjects: 40